# Value Radar: Altria and 10 Stock Gems! Newsy: Value Investor Weekly Published: 2026-05-07T12:30:00.250Z Source: https://newsyai.com/edition/c05f9cf2-a45a-43d8-833c-0a172ed970fb Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: Altria Group (MO) & 10 Fresh Picks! **Date: May 07, 2026 (United States)** **Market anchor:** The U.S. 10-year Treasury yield stands at 4.35% today, easing slightly from last week's 4.36% amid steady economic signals.[[1]](https://tradingeconomics.com/united-states/government-bond-yield)[[2]](https://ycharts.com/indicators/10_year_treasury_rate) --- ## 10 Fresh Value Candidates Here are 10 new stocks trading at discounts to their fundamentals—screened for forward price-to-earnings ratios under 20x (where applicable), yields above 3%, reliable cash flow generation, and sturdy balance sheets. These are fresh picks, avoiding repeats from prior editions. - **Altria Group (MO)**: Top U.S. cigarette maker shifting to oral nicotine; 5.8% yield, forward 13x P/E, strong free cash flow.[[3]](https://finance.yahoo.com/quote/MO/key-statistics)[[4]](https://www.koyfin.com/company/mo/dividends) - **Philip Morris International (PM)**: Global smoke-free leader; 3.5% yield, forward 20x P/E, robust margins.[[5]](https://finance.yahoo.com/quote/PM/key-statistics)[[6]](https://www.gurufocus.com/term/forward-pe-ratio/PM) - **British American Tobacco (BTI)**: Diversified tobacco giant; ~8% yield, low teens P/E, buyback support.[[7]](https://seekingalpha.com/symbol/PM/peers/comparison) - **Ford Motor (F)**: Auto turnaround with hybrids; 5.5% yield, forward 8x P/E, improving cash flow.[[8]](https://www.forbes.com/sites/investor-hub/article/best-undervalued-stocks-buy-april-2026) - **Boeing (BA)**: Aerospace recovery play; ~0% yield but sub-15x forward P/E, order backlog.[[9]](https://www.nerdwallet.com/investing/learn/undervalued-stocks) - **Pfizer (PFE)**: Pharma value with pipeline; 5.5% yield, forward 10x P/E, cash rich.[[10]](https://www.ebc.com/forex/best-cheap-stocks-to-buy-now-top-7-undervalued-stocks-picks-for-2026) - **AbbVie (ABBV)**: Biopharma steady grower; 3.5% yield, forward 14x P/E, Humira successors.[[11]](https://money.usnews.com/investing/articles/best-dividend-stocks-to-buy-this-year) - **TotalEnergies (TTE)**: Energy major; 4.5% yield, forward 7x P/E, strong balance sheet.[[8]](https://www.forbes.com/sites/investor-hub/article/best-undervalued-stocks-buy-april-2026) - **Kimberly-Clark (KMB)**: Consumer essentials; 3.5% yield, forward 16x P/E, pricing power.[[12]](https://money.usnews.com/investing/articles/best-high-dividend-low-volatility-stocks-to-buy) - **Williams Companies (WMB)**: Natural gas pipelines; 4.2% yield, forward 15x P/E, fee-based cash flows.[[12]](https://money.usnews.com/investing/articles/best-high-dividend-low-volatility-stocks-to-buy) ## Altria Group (MO): The Deep Dive Altria Group emerges as the top pick—a leading U.S. tobacco company owning Marlboro (over 40% market share) and expanding into oral nicotine pouches like on!. At ~$73/share (~$122B market cap), it yields 5.8%, trades at forward 13x earnings, and pumps out reliable free cash flow despite declining cigarette volumes, offset by pricing and new products.[[3]](https://finance.yahoo.com/quote/MO/key-statistics)[[13]](https://www.gurufocus.com/term/ForwardDividendYield/MO) Recent Q1 strength reaffirms guidance, making it a high-yield defensive value play.[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx) ### Business Overview Altria focuses on smokeable products (~90% revenue: cigarettes, cigars) and oral tobacco (on!, Black & Mild). - **2026 Q1 Results**: Revenue $4.76B (+2% adjusted), net earnings $2.18B, adjusted EPS $1.36 (beat estimates). TTM revenue ~$20.5B, EBITDA margins ~50%, free cash flow ~$9B annually. Dividend $4.24/share (73% payout, covered 1.3x by FCF). Debt ~$25B (net leverage ~4x EBITDA, investment-grade rated), shares outstanding 1.67B.[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx)[[3]](https://finance.yahoo.com/quote/MO/key-statistics)[[15]](https://www.macrotrends.net/stocks/charts/MO/altria/free-cash-flow) ### Roadmap and Growth Catalysts - **2026 Guidance**: Adjusted EPS $5.56–$5.72 (+2.5–5.5%), weighted to H2. Oral nicotine pouches up 20%+ shipment share gain; on! PLUS nationwide rollout.[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx)[[16]](https://investor.altria.com/press-releases/news-details/2026/on-PLUS-Expands-Nationwide-Retail-Availability/default.aspx) Long-term: 3–5% EPS growth via 5–7% pricing, smokeless expansion (oral industry +9.5% H1).[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx) $2.5B+ annual FCF funds 75%+ dividend hikes, buybacks (~4.5M shares Q1).[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx) ### Current Landscape and Risks U.S. adult smoking rate hit record low 9.9% (down from 10.8%), driving ~5% annual cigarette volume decline—but pricing +6–8% sustains revenue. Oral nicotine booms (industry +9.5%). Moats: Brand loyalty, distribution. Beta 0.72 (defensive). Risks: Regulation/tax hikes, slower oral ramp, litigation.[[17]](https://www.aha.org/news/headline/2026-03-18-report-cigarette-smoking-rate-drops-record-low-99)[[18]](https://www.alphaspread.com/security/nyse/mo/discount-rate) ### Valuation: Ground-Up DCF and Comparables **Step 1: Key Assumptions (Cross-Referenced)** - **FCFF 2026**: $9.4B (mid EPS $5.64 × 1.67B shares ≈ NI; FCF ≈ NI + $1.5B dep – $0.5B capex; aligns Q1 strength, historical $8.6–9.1B).[[14]](https://investor.altria.com/press-releases/news-details/2026/Altria-Reports-2026-First-Quarter-Results-Reaffirms-Full-Year-Guidance/default.aspx)[[15]](https://www.macrotrends.net/stocks/charts/MO/altria/free-cash-flow)[[19]](https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-mo/altria-group/news/is-it-time-to-reassess-altria-group-mo-after-its-strong-mult-1) Explicit growth 3% (pricing 6% – volumes 4% + oral; LT EPS proxy 3–5%). Terminal 2.5% (mature, inflation-adjusted).[[20]](https://investor.altria.com/press-releases/news-details/2026/Altria-Presents-as-Part-of-the-Consumer-Analyst-Group-of-New-York-Conference-Reaffirms-2026-Full-Year-Earnings-Guidance/default.aspx) - **WACC 6.5%**: Rf 4.35%, beta 0.72, ERP 5% → CoE 8.95%; debt cost 4.5% after-tax (21% rate), ~40% debt weight. Matches Guru 5.4%, VI 6.3%, Alpha ~6.5%.[[1]](https://tradingeconomics.com/united-states/government-bond-yield)[[21]](https://www.gurufocus.com/term/wacc/MO)[[22]](https://valueinvesting.io/MO/valuation/wacc) - **Net debt $26B**, shares 1.67B.[[3]](https://finance.yahoo.com/quote/MO/key-statistics) **Step 2: FCFF Projections ($B)** | Year | FCFF | PV @6.5% | |------|--------|----------| | 2026 | 9.40 | 8.82 | | 2027 | 9.68 | 8.54 | | 2028 | 9.97 | 8.27 | | 2029 | 10.27 | 8.01 | | 2030 | 10.58 | 7.76 | | Terminal | - | 162.2 | | **Total EV** | | **$204B** | *Terminal: $10.58B × 1.025 / (6.5% – 2.5%) = $181B (PV factor 0.896).* Equity value: $204B – $26B = $178B → **$107/share**. Sensitivity: WACC 7% → $95/share; 3.5% growth → $120/share; 6% WACC/2% term → $92/share.[[23]](https://valueinvesting.io/MO/valuation/dcf-growth-exit-5y) **Step 3: Comparables Check** Peers (PM EV/EBITDA 17x, BTI ~12x): Avg 14–16x. MO current 8x ~$11B EBITDA = ~$88B EV; fair 13x = $143B EV → $70 equity/share. Forward P/FCF 12–14x peers vs. MO 13x $9.4B = aligns $110/share.[[24]](https://valueinvesting.io/PM/valuation/ev_ebitda-multiples)[[25]](https://www.investing.com/pro/NYSE:MO/explorer/ev_to_ebitda_ltm) **Valuation Range: $95–$115/share** (30–55% upside). 5.8% yield + 4% growth crushes Treasuries; classic value amid decline fears. ### Investment Recommendation **Accumulate MO below $70**. ~10% total yield + oral upside debunks "dying industry" chatter—cash machine for patient investors. Watch Q2 for pouch momentum.[[26]](https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-mo/altria-group/news/is-it-time-to-reassess-altria-group-mo-after-its-strong-rece)